Idera Buys Rare Disease-Focused Aceragen in All-Stock Deal
What caught Idera’s attention was Aceragen’s lead assets, including ACG-701, which is set to enter phase 2 trials later this year for acute pulmonary exacerbations associated with cystic fibrosis. Although sodium fusidate has been used in this indication for decades in the U.K. and Australia, it has yet to receive approval in the U.S.
ACG-701 is also undergoing a phase 2 trial as a potential treatment for a life-threatening infection called melioidosis, with an interim readout expected in the first quarter of next year.
The other cornerstone of Aceragen’s portfolio is ACG-801, a biologic enzyme replacement therapy that is due to enter clinical trials for Farber disease in the first quarter of 2023. The drug was itself acquired from Enzyvant by Aceragen shortly after the company launched last year.
Read the full article at: www.fiercebiotech.com
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
